4,773 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AMI Asset Management Corp

AMI Asset Management Corp purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,773 shares of the biopharmaceutical company's stock, valued at approximately $1,104,000.

Several other hedge funds have also recently modified their holdings of MDGL. Montag A & Associates Inc. grew its stake in Madrigal Pharmaceuticals by 223.3% during the 3rd quarter. Montag A & Associates Inc. now owns 194 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 134 shares in the last quarter. Global Retirement Partners LLC grew its stake in Madrigal Pharmaceuticals by 454.5% during the 4th quarter. Global Retirement Partners LLC now owns 122 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 100 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Madrigal Pharmaceuticals during the 1st quarter valued at about $55,000. China Universal Asset Management Co. Ltd. grew its stake in Madrigal Pharmaceuticals by 95.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 468 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 228 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at about $72,000. Institutional investors and hedge funds own 98.50% of the company's stock.

Madrigal Pharmaceuticals Stock Up 3.2 %

Shares of MDGL traded up $8.23 during midday trading on Friday, reaching $267.04. The stock had a trading volume of 441,995 shares, compared to its average volume of 721,563. Madrigal Pharmaceuticals, Inc. has a 1-year low of $119.76 and a 1-year high of $322.67. The company's fifty day simple moving average is $237.60 and its two-hundred day simple moving average is $202.01. The company has a market cap of $5.31 billion, a price-to-earnings ratio of -13.39 and a beta of -0.48. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.38 and a quick ratio of 5.38.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) EPS for the quarter, missing analysts' consensus estimates of ($5.26) by ($0.42). During the same quarter in the previous year, the firm earned ($4.98) EPS. Equities research analysts expect that Madrigal Pharmaceuticals, Inc. will post -21.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Citigroup increased their price target on shares of Madrigal Pharmaceuticals from $382.00 to $389.00 and gave the company a "buy" rating in a research note on Friday, March 15th. TD Cowen increased their price target on shares of Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the company an "outperform" rating in a research note on Friday, March 15th. UBS Group increased their price target on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Canaccord Genuity Group increased their price target on shares of Madrigal Pharmaceuticals from $338.00 to $377.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Finally, JMP Securities increased their price target on shares of Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the company an "outperform" rating in a research note on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Madrigal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $377.40.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.